EP Patent

EP3736334A1 — Rnai compositions to treat apoc3-related diseases

Assigned to Arrowhead Pharmaceuticals Inc · Expires 2020-11-11 · 6y expired

What this patent protects

The present disclosure relates to compositions and methods for treating APOC3-related diseases such as : hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type…

USPTO Abstract

The present disclosure relates to compositions and methods for treating APOC3-related diseases such as : hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.

Drugs covered by this patent

Patent Metadata

Patent number
EP3736334A1
Jurisdiction
EP
Classification
—
Expires
2020-11-11
Drug substance claim
No
Drug product claim
No
Assignee
Arrowhead Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.